COLLEGE STATION, Texas--(BUSINESS WIRE)--Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the GMP production of cell and gene therapies (CGT), today announced the appointment of Laura Parks as executive vice president of Commercial Operations and Heather N.

德克萨斯大学站-（商业线）-Matica Biotechnology，Inc。（Matica Bio），一家专门从事细胞和基因治疗（CGT）GMP生产的合同开发和制造组织（CDMO），今天宣布任命Laura Parks担任商业运营和Heather N.的执行副总裁。

Sugrue as vice president of Alliance Management..

苏格鲁担任联盟管理副总裁。。

Parks will drive Matica Bio’s commercial efforts, including sales team development, marketing, and strategy. She brings to the company more than two decades of business leadership experience, driving the development of high-performance, market-focused teams in the life sciences.

公园将推动Matica Bio的商业努力，包括销售团队开发，营销和战略。她为公司带来了二十多年的业务领导经验，推动了生命科学领域高绩效，以市场为中心的团队的发展。

Prior to Matica Bio, Parks served in senior roles for several life science companies and CDMOs, including Patheon Pharmaceuticals, where she led strategic commercial efforts, integrating diverse service offerings and driving global pricing initiatives. Before Patheon, Parks served as president of DSM Pharmaceuticals’ Finished Dose CDMO business unit after successfully leading its marketing and sales team.

在Matica Bio之前，Parks曾担任多家生命科学公司和CDMO的高级职位，其中包括Patheon Pharmaceuticals，在那里她领导战略商业努力，整合各种服务产品并推动全球定价计划。在Patheon之前，Parks在成功领导其营销和销售团队之后担任DSM制药公司完成剂量CDMO业务部门的总裁。

She earned a Ph.D. in food science from the University of Georgia and a Bachelor of Science from Ohio State University..

她获得佐治亚大学食品科学博士学位和俄亥俄州立大学理学学士学位。。

“I’m excited to join Matica Bio’s team of highly experienced CGT manufacturing professionals, and to support biopharmaceutical developers in their mission to produce therapies that improve the lives of patients,” said Parks. “I’m particularly excited to be working in Texas alongside some of the industry’s brightest scientists in a purpose-built GMP facility, accelerating the path to market of clients’ life-changing therapies.”.

帕克斯说：“我很高兴加入Matica Bio的经验丰富的CGT制造专业团队，并支持生物制药开发商的使命，以生产改善患者生活的疗法。”。“我特别高兴在德克萨斯州与一些行业最聪明的科学家一起工作，建立一个专门建造的GMP设施，加速客户改变生命疗法市场的道路。”。

Sugrue will oversee Matica Bio’s business development strategy and execution for the company’s Alliance Management division. An accomplished leader in the life sciences, Sugrue has led the growth of several business development teams across notable companies including Catalent Pharma Solutions, where she managed the sales team for the company’s CGT services as the North American head of business development..

Sugrue将监督Matica Bio的业务发展战略和公司联盟管理部门的执行。Sugrue是生命科学领域的杰出领导者，领导着包括Catalent Pharma Solutions在内的知名公司的多个业务开发团队的发展，在那里她作为北美业务开发负责人管理公司CGT服务的销售团队。。

Prior to Catalent, Sugrue’s previous appointments included VP of sales at Syngene, VP of sales and marketing for Societal (previously Recro) and senior director of business development at Patheon Inc. Sugrue earned her master’s degree in chemistry from Boston University, and a bachelor's degree in chemistry from Ithaca College..

在Catalent之前，Sugrue之前的任命包括Syngene销售副总裁，社会销售和营销副总裁（以前是Recro）和Patheon Inc.业务发展高级总监.Sugrue在波士顿大学获得化学硕士学位，并获得学士学位伊萨卡学院化学系。。

“CGT is the future of medicine, and Matica has spent the last three years building state-of-the-art facilities and recruiting an outstanding team of technical experts, making them the partnering CDMO of choice for CGT drug development,” Sugrue said. “In addition, they have created a data-driven, system-based approach to gene therapy, coupled with a customized cell line, MatiMax, which addresses every aspect of cell line optimization, and utilizes innovative processes and advanced analytics to develop assays.

Sugrue说：“CGT是医学的未来，Matica在过去三年中一直在建立最先进的设施并招募杰出的技术专家团队，使其成为CGT药物开发的首选合作CDMO。”。“此外，他们还创建了一种数据驱动的，基于系统的基因治疗方法，再加上定制的细胞系MatiMax，它解决了细胞系优化的各个方面，并利用创新的流程和先进的分析方法来开发检测方法。

There’s never been a more exciting time to work in CGT, and I’m honored to join the Matica team to help further drive the growth of this CGT-specialized CDMO as VP of alliance management.”.

在CGT工作从来没有一个更激动人心的时刻，我很荣幸加入Matica团队，帮助进一步推动这个CGT专业CDMO作为联盟管理副总裁的发展。

“Laura and Heather have sustained impressive careers in life sciences leadership,” said Yun Jeong Song, M.D., president and chief executive officer of Matica Bio. “Their expertise will be an invaluable addition to Matica Bio as we serve our clients through our innovative manufacturing solutions in this rapidly growing industry.”.

Matica Bio的总裁兼首席执行官宋云全说：“Laura和Heather在生命科学领导力方面取得了令人瞩目的职业生涯。”他们的专业知识将成为Matica Bio的宝贵补充，因为我们通过我们在这个快速发展的行业中的创新制造解决方案为客户服务“。

About Matica Biotechnology, Inc.

关于Matica Biotechnology，Inc。

Matica Biotechnology, Inc. (Matica Bio) is a contract development and manufacturing organization (CDMO) specializing in fully integrated cell and gene therapy manufacturing. The industry-leading experts at our state-of-the-art facility in College Station, Texas, deliver breakthrough therapies rapidly and safely through innovative manufacturing solutions.

Matica Biotechnology，Inc。（Matica Bio）是一家合同开发和制造组织（CDMO），专门从事完全整合的细胞和基因治疗制造。我们位于德克萨斯州大学城的最先进设施的行业领先专家通过创新的制造解决方案快速安全地提供突破性治疗。

Advance your therapy from idea to patient with the experts at Matica Bio. Visit www.maticabio.com..

与Matica Bio的专家一起推进您的治疗方案。访问www.maticabio.com。。